Onco Wiki / Maladie

Lymphome nodulaire à prédominance cellulaire B (anciennement NLPHL)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-NLPBL
TypeMaladie
Alias
Hodgkin (héritage) prédominant des lymphocytesNLPBLNLPHLLymphome nodulaire prédominant des cellules BНодулярна лімфоцит-домінантна B-клітинна лімфома (раніше NLPHL)
Étatreviewed 2026-04-25 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-NCCN-BCELL-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology9659/3
icd_10C81.0
who_classificationMature B-cell neoplasms — Nodular lymphocyte-predominant B-cell lymphoma per WHO 5th ed. (RECLASSIFIED from Hodgkin to B-cell in 5th ed.)

Capacités

Notes

WHO 5th-ed renamed NLPHL → NLPBL (now classified as B-cell, not Hodgkin). CD20+ → rituximab-responsive. Early-stage: ISRT alone curative in many. Advanced: R-CHOP-like (rituximab + chemo, reusing DLBCL pathway) preferred over ABVD.

Utilisé par

Pertinence thérapeutique

Algorithmes

Maladie

Indication

Questionnaires

Signal d’alerte

Sources